Clinical Pharmacokinetics

, Volume 31, Issue 3, pp 198–214 | Cite as

Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine

An Update
  • Edoardo Spina
  • Franco Pisani
  • Emilio Perucca
Drug Interaction

Summary

Carbamazepine is one of the most commonly prescribed antiepileptic drugs and is also used in the treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar depression. Because of its widespread and long term use, carbamazepine is frequently prescribed in combination with other drugs, leading to the possibility of drug interactions.

The most important interactions affecting carbamazepine pharmacokinetics are those resulting in induction or inhibition of its metabolism. Phenytoin, phenobarbital (phenobarbitone) and primidone accelerate the elimination of carbamazepine, probably by stimulating cytochrome P450 (CYP) 3A4, and reduce plasma carbamazepine concentrations to a clinically important extent.

Inhibition of carbamazepine metabolism and elevation of plasma carbamazepine to potentially toxic concentrations can be caused by stiripentol, remacemide, acetazolamide, macrolide antibiotics, isoniazid, metronidazole, certain antidepressants, verapamil, diltiazem, cimetidine, danazol and (dextropropoxyphene) propoxyphene. In other cases, toxic symptoms may result from elevated plasma concentrations of the active metabolite carbamazepine-10,11-epoxide, due to the inhibition of epoxide hydrolase by valproic acid (sodium valproate), valpromide, valnoctamide and progabide.

Carbamazepine is a potent inducer of CYP3A4 and other oxidative enzyme system in the liver, and it may also increase glucuronyltransferase activity. This results in the acceleration of the metabolism of concurrently prescribed anticonvulsants, particularly valproic acid, clonazepam, ethosuximide, lamotrigine, topiramate, tiagabine and remacemide.

The metabolism of many other drugs such as tricyclic antidepressants, anti-psychotics, steroid oral contraceptives, glucocorticoids, oral anticoagulants, cyclosporin, theophylline, chemotherapeutic agents and cardiovascular drugs can also be induced, leading to a number of clinically relevant drug interactions.

Interactions with carbamazepine can usually be predicted on the basis of the pharmacological properties of the combined drug, particularly with respect to its therapeutic index, site of metabolism and ability to affect specific drug metabolising isoenzymes. Avoidance of unnecessary polypharmacy, selection of alternative agents with lower interaction potential, and careful dosage adjustments based on serum drug concentration monitoring and clinical observation represent the mainstays for the minimisation of risks associated with these interactions.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982; 7: 57–84PubMedGoogle Scholar
  2. 2.
    Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33: 139–44PubMedGoogle Scholar
  3. 3.
    Perucca E, Richens A. Antiepileptic drug interactions. In: Janz D, Frey HH, editors. Antiepileptic drugs: handbook of experimental pharmacology. Vol. 74. Berlin: Springer-Verlag, 1985: 831–55Google Scholar
  4. 4.
    Perucca E, Richens A. Interactions between drugs used in the treatment of epilepsy. In: Pitlick WH, editor. Antiepileptic drug interactions. New York: Demos Publishers, 1989: 27–38Google Scholar
  5. 5.
    Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986; 8: 305–17PubMedGoogle Scholar
  6. 6.
    Pisani F, Perucca E, Di Perri R. Clinically relevant anti-epileptic drug interactions. J Int Med Res 1990; 18: 1–15PubMedGoogle Scholar
  7. 7.
    Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part I. J Clin Psychopharmacol 1991; 11: 198–203PubMedGoogle Scholar
  8. 8.
    Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine. Part II. J Clin Psychopharmacol 1991; 11: 306–13PubMedGoogle Scholar
  9. 9.
    Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156–84PubMedGoogle Scholar
  10. 10.
    Levy RH, Wurden CJ. Carbamazepine: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Anti-epileptic drugs. New York: Raven Press, 1995: 543–53Google Scholar
  11. 11.
    Anderson GD, Graves NM. Drug interactions with antiepileptic agents: prevention and management. CNS Drugs 1994; 2: 268–79Google Scholar
  12. 12.
    Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3: 128–43PubMedGoogle Scholar
  13. 13.
    Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986; 11: 177–98PubMedGoogle Scholar
  14. 14.
    Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969–79PubMedGoogle Scholar
  15. 15.
    Nebert DW, Nelson DR, Coon MJ, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1–14PubMedGoogle Scholar
  16. 16.
    Johnson CM, Thummel KE, Kroetz DL, et al. Metabolism of CBZ by cytochrome P450 isoforms 3A4, 2C8 and 1A2. Pharm Res 1992; 9 Suppl.: 301Google Scholar
  17. 17.
    Eichelbaum M, Ekbom B, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 1975; 8: 337–41PubMedGoogle Scholar
  18. 18.
    Pitlick WH, Levy RH, Troupin AS, et al. Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 1976; 65: 462PubMedGoogle Scholar
  19. 19.
    Bertilsson L, Hojer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther 1980; 27: 83–8PubMedGoogle Scholar
  20. 20.
    Neef C, Van Der Straaten V. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988; 43: 372–5PubMedGoogle Scholar
  21. 21.
    Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17: 51–7PubMedGoogle Scholar
  22. 22.
    Mattson GF, Mattson RH, Cramer JA. Interaction between valproic acid and carbamazepine: an in vitro study of protein binding. Ther Drug Monit 1982; 4: 181–4PubMedGoogle Scholar
  23. 23.
    Macphee GJA, Thompson GG, Mclnnes GT, et al. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; I: 700–3Google Scholar
  24. 24.
    Pisani F, Oteri G, Di Perri R. Valproic acid fails to displace phenobarbitone and carbamazepine from plasma protein binding sites in epileptic patients. Br J Clin Pharmacol 1981; 12: 81–3PubMedGoogle Scholar
  25. 25.
    McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981; 3: 63–70PubMedGoogle Scholar
  26. 26.
    Brodie MJ, Forrest G, Rapeport WG. Carbamazepine-10,11 -epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants. Br J Clin Pharmacol 1983; 16: 747–50PubMedGoogle Scholar
  27. 27.
    Levy RH, Moreland TA, Morselli PL, et al. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia 1984; 25: 338–45PubMedGoogle Scholar
  28. 28.
    Perucca E, Richens A. General principles: biotransformation. In: Levy RH, Mattson R, Meldrum B, et al., editors. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989: 23–48Google Scholar
  29. 29.
    Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interaction with carbamazepine in epileptic patients. Epilepsia 1986; 27: 548–52PubMedGoogle Scholar
  30. 30.
    Pisani F, Caputo M, Fazio A, et al. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia 1990; 31: 339–42PubMedGoogle Scholar
  31. 31.
    Meijer JWA, Binnie CD, Debets RMC, et al. Possible hazard of valpromide-carbamazepine combination therapy in epilepsy. Lancet 1984; I: 802Google Scholar
  32. 32.
    Levy RH, Kerr BM, Loiseau P, et al. Inhibition of carbamazepine epoxide elimination by valpromide and valproic acid. Epilepsia 1986; 27: 592Google Scholar
  33. 33.
    Pisani F, Fazio A, Oteri G, et al. Effect of valpromide on the pharmacokinetics of carbamazepine-10,11 -epoxide. Br J Clin Pharmacol 1988; 25: 611–3PubMedGoogle Scholar
  34. 34.
    Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 1989; 46: 82–93PubMedGoogle Scholar
  35. 35.
    Pacifici GM, Tomson T, Bertilsson L, et al. Valpromide/carbamazepine and risk of teratogenicity. Lancet 1985; I: 397–8Google Scholar
  36. 36.
    Pacifici GM, Franchi M, Bencini C, et al. Valpromide inhibits human epoxide hydrolase. Br J Clin Pharmacol 1986; 22: 269–74PubMedGoogle Scholar
  37. 37.
    Pacifici GM, Rane A. Valpromide but not sodium hydrogen divalproate inhibits epoxide hydrolase in human liver. Pharmacol Toxicol 1987; 60: 237–8PubMedGoogle Scholar
  38. 38.
    Pisani F, Fazio A, Artesi C, et al. Impairment of carbamazepine-10,11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects. Br J Clin Pharmacol 1992; 34: 85–7PubMedGoogle Scholar
  39. 39.
    Pisani F, Haj-Yehia A, Fazio A, et al. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia 1993; 34: 954–9PubMedGoogle Scholar
  40. 40.
    Graves NM, Ritter FJ, Wagner ML, et al. Effect of lamotrigine on carbamazepine epoxide concentrations. Epilepsia 1991; 32 Suppl. 3: 13Google Scholar
  41. 41.
    Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11: 147–50PubMedGoogle Scholar
  42. 42.
    Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433–43PubMedGoogle Scholar
  43. 43.
    Pisani F, Xiao B, Fazio A, et al. Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Res 1994; 19: 245–8PubMedGoogle Scholar
  44. 44.
    Leach JP, Blacklaw J, Stewart M, et al. Mutual pharmacokinetic interactions between remacemide hydrochloride and carbamazepine. Epilepsia 1995; 36 Suppl. 3: S163Google Scholar
  45. 45.
    Loiseau P, Tor J. Stiripentol in absence seizures. Epilepsia 1987; 28: 579Google Scholar
  46. 46.
    Levy RH, Loiseau P, Guyot M, et al. Effects of stiripentol on valproate plasma level and metabolism. Epilepsia 1987; 28: 605Google Scholar
  47. 47.
    Levy RH, Martinez-Lage M, Kerr BM, et al. Effect of stiripentol on the formation and elimination of carbamazepine epoxide [abstract no. 71]. 17th International Epilepsy Congress: 1987 Sep 6–11; JerusalemGoogle Scholar
  48. 48.
    Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P450 inhibition by stiripentol. Epilepsia 1991; 32: 267–74PubMedGoogle Scholar
  49. 49.
    Kutt H, Solomon GE, Dhar AK, et al. Effects of progabide on carbamazepine epoxide and carbamazepine concentrations in plasma. Epilepsia 1984; 25: 684Google Scholar
  50. 50.
    Bianchetti G, Padovani P, Thenot JP, et al. Pharmacokinetic interactions of progabide with other antiepileptic drugs. Epilepsia 1987; 28: 68–73PubMedGoogle Scholar
  51. 51.
    Graves NM, Fuerst RH, Cloyd JC, et al. Progabide-induced changes in carbamazepine metabolism. Epilepsia 1988; 29: 775–80PubMedGoogle Scholar
  52. 52.
    Kroetz DL, Loiseau P, Guyot M, et al. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 1993; 54: 485–97PubMedGoogle Scholar
  53. 53.
    McBride MC. Serum carbamazepine levels are increased by acetazolamide. Ann Neurol 1984; 16: 393Google Scholar
  54. 54.
    Munoz JJ, De Salamanca RE, Diaz-Obregon C, et al. The effect of clobazam on steady-state plasma concentrations of carbamazepine and its metabolites. Br J Clin Pharmacol 1990; 29: 763–5PubMedGoogle Scholar
  55. 55.
    Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (l,2-benzisoxazole-3-methanesulphonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 206–11PubMedGoogle Scholar
  56. 56.
    Browne TR, Szabo GK, Kres J, et al. Drug interactions of zonisamide (CI-912) with phenytoin and carbamazepine. J Clin Pharmacol 1986; 26: 555Google Scholar
  57. 57.
    Minami T, Ieiri I, Ohtsubo K, et al. Influence of additional therapy with zonisamide (Excegran) on protein binding and metabolism of carbamazepine. Epilepsia 1994; 35: 1023–5PubMedGoogle Scholar
  58. 58.
    Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51: 126PubMedGoogle Scholar
  59. 59.
    Bonnet P, Vandel S, Nezelof S, et al. Carbamazepine, fluoxetine. Is there a pharmacokinetic interaction? Therapie 1992; 47: 165PubMedGoogle Scholar
  60. 60.
    Grimsley SR, Jann MW, Carter G, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10–5PubMedGoogle Scholar
  61. 61.
    Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84: 583–4PubMedGoogle Scholar
  62. 62.
    Martinelli V, Bocchetta A, Palmas AM, et al. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 1993; 36: 615–6PubMedGoogle Scholar
  63. 63.
    Joblin M, Ghose K. Possible interaction of sertraline with carbamazepine. N Z Med J 1994; 107: 43PubMedGoogle Scholar
  64. 64.
    Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247–50PubMedGoogle Scholar
  65. 65.
    Gidal BE, Anderson GD, Seaton TL, et al. Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide. Ther Drug Monit 1993; 15: 405–9PubMedGoogle Scholar
  66. 66.
    Andersen BB, Mikkelsen M, Vesterager A, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991; 10: 201–4PubMedGoogle Scholar
  67. 67.
    Pisani F, Narbone MC, Fazio A, et al. Increased serum carbamazepine levels by viloxazine in epileptic patients. Epilepsia 1984; 25: 482–5PubMedGoogle Scholar
  68. 68.
    Pisani F, Fazio A, Oteri G, et al. Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiatry 1986; 49: 1142–5PubMedGoogle Scholar
  69. 69.
    Dravet C, Mesdjian E, Cenraud B, et al. Interaction between carbamazepine and triacetyloleandomycin. Lancet 1977; I: 810–1Google Scholar
  70. 70.
    Mesdjian E, Dravet C, Cenraud B, et al. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489–96PubMedGoogle Scholar
  71. 71.
    Hedrick R, Williams F, Morin R, et al. Carbamazepine-erythromycin leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit 1983; 5: 405–7PubMedGoogle Scholar
  72. 72.
    Vajda FJE, Bladin PF. Carbamazepine-erythromycin-base interaction [letter]. Med J Aust 1984; 140: 81PubMedGoogle Scholar
  73. 73.
    Carranco E, Kareus J, Co S, et al. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol 1985; 42: 187–8PubMedGoogle Scholar
  74. 74.
    Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983; 33: 460–4PubMedGoogle Scholar
  75. 75.
    Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82PubMedGoogle Scholar
  76. 76.
    Vincon G, Albin H, Demotes-Mainard F, et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 1987; 32: 321–3PubMedGoogle Scholar
  77. 77.
    Barzaghi N, Gatti C, Crema F, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharm Res 1988; 8: 101–5Google Scholar
  78. 78.
    O’Connor NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Farn Pract 1994; 7: 489–492Google Scholar
  79. 79.
    Couet W, Istin B, Ingrand I, et al. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Ther Drug Monit 1990; 12: 144–9PubMedGoogle Scholar
  80. 80.
    Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161–2PubMedGoogle Scholar
  81. 81.
    Rapeport WG, Dewland PM, Muirhead DC, et al. Lack of an interaction between azithromycin and carbamazepine [abstract]. Br J Clin Pharmacol 1992; 33: 551PGoogle Scholar
  82. 82.
    Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. BMJ 1982; 285: 261–2PubMedGoogle Scholar
  83. 83.
    Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa. N Engl J Med 1982; 307: 1325–7PubMedGoogle Scholar
  84. 84.
    Block SH. Carbamazepine-isoniazid interaction. Pediatrics 1982; 69: 494–5PubMedGoogle Scholar
  85. 85.
    Fleenor ME, Harden JW, Curtis G. Interaction between carbamazepine and antitubercolosis agents. Chest 1991; 99: 1554PubMedGoogle Scholar
  86. 86.
    Patterson BD. Possible interaction between metronidazole and carbamazepine. Ann Pharmacother 1994; 28: 1303–4PubMedGoogle Scholar
  87. 87.
    Beattie B, Biller J, Melhaus B, et al. Verapamil-induced carbamazepine neurotoxicity. Eur Neurol 1988; 28: 104–5PubMedGoogle Scholar
  88. 88.
    Price WA, DiMarzio LR. Verapamil-carbamazepine neurotoxicity. J Clin Psychiatry 1988; 49: 80PubMedGoogle Scholar
  89. 89.
    Brodie MJ, Macphee GJA. Carbamazepine neurotoxicity precipitated by diltiazem. BMJ 1986; 292: 1170–1PubMedGoogle Scholar
  90. 90.
    Eimer M, Carter BL. Elevated serum carbamazepine concentrations following diltiazem initiation. Drug Intell Clin Pharm 1987; 21: 340–2PubMedGoogle Scholar
  91. 91.
    Ahmad S. Diltiazem-carbamazepine interaction. Am Heart J 1990; 120: 1485PubMedGoogle Scholar
  92. 92.
    Gadde K, Calabrese JR. Diltiazem effect on carbamazepine levels in manic depression. J Clin Psychopharmacol 1990; 10: 378–9PubMedGoogle Scholar
  93. 93.
    Bahls FH, Ozuna J, Ritchie DE. Interaction between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991; 41: 740–2PubMedGoogle Scholar
  94. 94.
    Maoz E, Grossman E, Thaler M, et al. Carbamazepine neurotoxic reaction after administration of diltiazem. Arch Intern Med 1992; 152: 2503–4PubMedGoogle Scholar
  95. 95.
    Dam M, Kristensen B, Hansen SB, et al. Interaction between carbamazepine and propoxyphene in man. Acta Neurol Scand 1977; 56: 603–7PubMedGoogle Scholar
  96. 96.
    Dam M, Christiansen J. Interaction of propoxyphene with carbamazepine [letter]. Lancet 1977; I: 509Google Scholar
  97. 97.
    Hansen BS, Dam M, Brandt J, et al. Influence of dextropropoxyphene on steady-state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurol Scand 1980; 61: 357–67PubMedGoogle Scholar
  98. 98.
    Oles KS, Mirza W, Penry JK. Catastrophic neurologic signs due to drug interaction: tegretol and darvon. Surg Neurol 1989; 32: 144–51PubMedGoogle Scholar
  99. 99.
    Telerman-Toppet N, Duret ME, Coers C. Cimetidine interaction with carbamazepine [letter]. Ann Intern Med 1981; 94: 544PubMedGoogle Scholar
  100. 100.
    Webster LK, Mihaly GW, Jones DB, et al. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 1984; 27: 341–3PubMedGoogle Scholar
  101. 101.
    MacPhee GJA, Thompson GG, Scobie G, et al. Effect of cimetidine on carbamazepine auto- and hetero-induction in man. Br J Clin Pharmacol 1984; 18: 411–9PubMedGoogle Scholar
  102. 102.
    Dalton MJ, Powell JR, Messenheimer JA. The influence of cimetidine on single dose carbamazepine pharmacokinetics. Epilepsia 1985; 26: 127–30PubMedGoogle Scholar
  103. 103.
    Sonne J, Luddorf K, Larsen NE, et al. Lack of interaction between cimetidine and carbamazepine. Acta Neurol Scand 1983; 68: 253–6PubMedGoogle Scholar
  104. 104.
    Levine M, Jones MV, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology 1985; 35: 562–5PubMedGoogle Scholar
  105. 105.
    Dalton MJ, Powell JR, Messenheimer JA. Cimetidine and carbamazepine: a complex pharmacokinetic interaction [abstract]. Drug Intell Clin Pharm 1985; 19: 456Google Scholar
  106. 106.
    Kramer G, Theisohn M, von Unruh GE, et al. Carbamazepinedanazol drug interaction: its mechanism examined by a stable isotope technique. Ther Drug Monit 1986; 8: 387–92PubMedGoogle Scholar
  107. 107.
    Zielinsky JJ, Lichten EM, Haidukewych D. Clinically significant danazol-carbamazepine interaction. Ther Drug Monit 1987; 9: 24–7Google Scholar
  108. 108.
    Hayden M, Buchanan N. Danazol-carbamazepine interaction. Med J Aust 1991; 155: 851PubMedGoogle Scholar
  109. 109.
    Bourgeois BFD, Dodson WE, Ferrendelli JA. Interaction between primidone, carbamazepine, and nicotinamide. Neurology 1982; 32: 1122–6PubMedGoogle Scholar
  110. 110.
    Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. Clin Pharm 1986; 5: 817PubMedGoogle Scholar
  111. 111.
    Perucca E, Richens A. Reversal by phenytoin of carbamazepine-induced water intoxication: a pharmacokinetic interaction. J Neurol Neurosurg Psychiatry 1980; 43: 540–5PubMedGoogle Scholar
  112. 112.
    Christiansen J, Dam M. Influence of phenobarbital and diphenylidantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49: 543–6PubMedGoogle Scholar
  113. 113.
    Schneider H. Carbamazepine: the influence of other anti-epileptic drugs on its serum levels. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 189–96Google Scholar
  114. 114.
    Johannessen SI, Strandjord RE. The influence of phenobarbital and phenytoin on carbamazepine serum levels. In: Schneider H, Janz D, Gardner-Thorpe C, et al., editors. Clinical pharmacology of antiepileptic drugs. Berlin: Springer-Verlag, 1975: 201–5Google Scholar
  115. 115.
    Cereghino JJ, Brock JT, Van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733–41PubMedGoogle Scholar
  116. 116.
    Rane A, Hojer B, Wilson JT. Kinetics of carbamazepine and 10,11-epoxide metabolite in children. Clin Pharmacol Ther 1976; 19: 276–83PubMedGoogle Scholar
  117. 117.
    Lander CM, Eadie MJ, Tyrer JH. Factors influencing plasma carbamazepine concentration. Clin Exp Neurol 1977; 14: 184–93PubMedGoogle Scholar
  118. 118.
    Eichelbaum M, Kothe KW, Hoffman F. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin Pharmacol Ther 1979; 26; 366–71PubMedGoogle Scholar
  119. 119.
    Battino D, Bossi L, Croci D, et al. Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980; 2: 315–22PubMedGoogle Scholar
  120. 120.
    Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987; 9: 21–3PubMedGoogle Scholar
  121. 121.
    Tomson T, Spina E, Wedlund J-E. Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. Ther Drug Monit 1987; 9: 117–9PubMedGoogle Scholar
  122. 122.
    Dam M, Jensen A, Christiansen J. Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy. Acta Neurol Scand 1975; 60 Suppl.: 33–8Google Scholar
  123. 123.
    Korczyn AD, Ben-Zvi A, Kaplanski J, et al. Plasma levels of carbamazepine and metabolites: effect of enzyme inducers. In: Meinardi H, Rowan AJ, editors. Advances in epileptology. Amsterdam: Swets & Zeitlinger, 1978: 278–9Google Scholar
  124. 124.
    Westemberg HGM, van der Kleijn E, Oei TT, et al. Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23: 320–8Google Scholar
  125. 125.
    Bourgeois BFD, Wad N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther Drug Monit 1984; 6: 259–65PubMedGoogle Scholar
  126. 126.
    Eichelbaum M, Tomson T, Tybring G, et al. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10: 80–90PubMedGoogle Scholar
  127. 127.
    Spina E, Martines C, Fazio A, et al. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther Drug Monit 1991; 13: 109–12PubMedGoogle Scholar
  128. 128.
    Kroetz DL, Kerr BM, McFarland LV, et al. Measurement of in vivo microsomal epoxide hydrolase activity in white subjects. Clin Pharmacol Ther 1993; 53: 306–15PubMedGoogle Scholar
  129. 129.
    Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041–65PubMedGoogle Scholar
  130. 130.
    Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991; 32: 130–2PubMedGoogle Scholar
  131. 131.
    Wagner ML, Remmel RP, Graves NM, et al. Effect of felbamate on carbamazepine and its major metabolites. Clin Pharmacol Ther 1993; 53: 536–43PubMedGoogle Scholar
  132. 132.
    Perucca E, Richens A. Biotransformation. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 31–50Google Scholar
  133. 133.
    Wietholz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989; 36: 401–6Google Scholar
  134. 134.
    Shaw PN, Houston JB, Rowland M, et al. Antipyrine metabolite kinetics in healthy human volunteers during multile dosing of phenytoin and carbamazepine. Br J Clin Pharmacol 1985; 20: 611–8PubMedGoogle Scholar
  135. 135.
    Hansen JM, Siersboeck-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971; 12: 539–43PubMedGoogle Scholar
  136. 136.
    Cereghino JJ, Van Meter JC, Brock JT, et al. Preliminary observations of serum carbamazepine concentrations in epileptic patients. Neurology 1973; 23: 357–66PubMedGoogle Scholar
  137. 137.
    Hooper WD, Dubetz DK, Eadie MJ, et al. Preliminary observations on the clinical pharmacology of carbamazepine. Proc Aust Assoc Neurol 1974; 11: 189–98PubMedGoogle Scholar
  138. 138.
    Windorfer A, Sauer W. Drug interactions during anticonvulsant therapy in childhood; diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepine and dipropylacetate. Neuropediatrics 1979; 8: 29–41Google Scholar
  139. 139.
    Lai ML, Lin TS, Huang JD. Effect of single- and multiple-dose carbamazepine on the pharmacokinetics of diphenylhydantoin. Eur J Clin Pharmacol 1992; 43: 201–3PubMedGoogle Scholar
  140. 140.
    Browne TR, Evans JH, Szabo GK, et al. Effect of carbamazepine on phenytoin pharmacokinetics determined by a stable isotope technique. Neurology 1984; 35: 284Google Scholar
  141. 141.
    Browne TR, Szabo GK, Evans JH, et al. Carbamazepine increases phenytoin serum concentrations and reduces phenytoin clearance. Neurology 1988; 38: 1146–50PubMedGoogle Scholar
  142. 142.
    Coper H, von Herrath U. Pharmacokinetic investigation on the combination of diphenylhydantoin and carbamazepine. Epilepsia 1973; 14: 466–67Google Scholar
  143. 143.
    Lander CM, Eadie MJ, Tyrer JH. Interactions between anticonvulsants. Proc Aust Assoc Neurol 1975; 12: 111–6PubMedGoogle Scholar
  144. 144.
    Gratz ES, Theodore WH, Newmark ME, et al. Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures. Neurology 1982; 32: A223Google Scholar
  145. 145.
    Zielinski JJ, Haidukewych D, Leheta BJ. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. Ther Drug Monit 1985; 7: 51–3PubMedGoogle Scholar
  146. 146.
    Callaghan N, Feely M, Duggan F, et al. The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels. Acta Neurol Scand 1977; 56: 1–7PubMedGoogle Scholar
  147. 147.
    Eadie MJ, Lander CM, Hooper WD, et al. Factors influencing phenobarbitone levels in epileptic patients. Br J Clin Pharmacol 1977; 4: 541–7PubMedGoogle Scholar
  148. 148.
    Warren JW, Benmaman JD, Wannamaker BB, et al. Kinetics of carbamazepine-ethosuximide interaction. Clin Pharmacol Ther 1980; 28: 646–51PubMedGoogle Scholar
  149. 149.
    Gatti G, Bartoli A, Marchiselli R, et al. Elevation of ethosuximide clearance in patients receiving concurrent treatment with enzyme inducing antiepileptic drugs [abstract no. 158]. First Congress of the European Association for Clinical Pharmacology and Therapeutics: 1995 Sep 27–30; ParisGoogle Scholar
  150. 150.
    Bowdle TA, Levy RH, Cutler RE. Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 1979; 26: 629–34PubMedGoogle Scholar
  151. 151.
    Mihaly GW, Vajda FJ, Miles JL, et al. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. Eur J Clin Pharmacol 1979; 16: 23–9PubMedGoogle Scholar
  152. 152.
    Reunanen MI, Luoma P, Myllyla VV, et al. Low serum valproic acid concentrations in epileptic patients on combination therapy. Curr Ther Res Clin Exp 1980; 28: 456–62Google Scholar
  153. 153.
    Panesar SK, Orr JM, Farrel K, et al. The effect of carbamazepine on valproic acid disposition in adult volunteers. Br J Clin Pharmacol 1989; 27: 323–8PubMedGoogle Scholar
  154. 154.
    Perucca E, Gatti G, Frigo GM, et al. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 495–9PubMedGoogle Scholar
  155. 155.
    Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990; 48: 225–35PubMedGoogle Scholar
  156. 156.
    Jann MW, Fidone GS, Israel MK, et al. Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 1988; 29: 578–81PubMedGoogle Scholar
  157. 157.
    Binnie CD, van Emde Boas W, Kastelijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248–4PubMedGoogle Scholar
  158. 158.
    Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single dose pharmacokinetics and initial 1-week experience in refractory epilepsy. Epilepsy Res 1987; 1: 194–201PubMedGoogle Scholar
  159. 159.
    Doose DR, Gisclon LG, Liao S, et al. Pharmacokinetics of topiramate. Adv Antiepiletic Drug Ther 1995; 1: 7–16Google Scholar
  160. 160.
    Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996. In pressGoogle Scholar
  161. 161.
    Leppik IE, So E, Pask CA, et al. Pharmacokinetic study of tiagabine HCl in patients at multiple steady-state dose. Epilepsia 1993; 34 Suppl. 6: 355Google Scholar
  162. 162.
    Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984; 36: 661–9PubMedGoogle Scholar
  163. 163.
    Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760–87PubMedGoogle Scholar
  164. 164.
    Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8: 293–6PubMedGoogle Scholar
  165. 165.
    Rey E, Pons G, Olive G. Vigabatrin clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 267–78PubMedGoogle Scholar
  166. 166.
    Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, editor. New trends in epilepsy management. London: Royal Society of Medicine Services Ltd, 1993: 41–6Google Scholar
  167. 167.
    Levy RH, Lane EA, Guyot M, et al. Analysis of parent drug-metabolite relationship in the presence of an inducer, application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 1983; 11: 286–92PubMedGoogle Scholar
  168. 168.
    Jawad S, Richens A. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. Br J Clin Pharmcol 1984; 18: 873–7Google Scholar
  169. 169.
    Bun H, Monjanel-Mouterde S, Noel F, et al. Effect of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethyclobazam. Pharmacol Toxicol 1990; 67: 136–40PubMedGoogle Scholar
  170. 170.
    Sennoune S, Mesdjian E, Bonneton J, et al. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14: 269–74PubMedGoogle Scholar
  171. 171.
    Dhillon S, Richens A. Pharmacokinetics of diazepam in epileptic patients and normal volunteers following intravenous administration. Br J Clin Pharmacol 1981; 12: 841–4PubMedGoogle Scholar
  172. 172.
    Lai AA, Levy RH, Cutter RE. Time-course of interactions between carbamazepine and clonazepam. Clin Pharmacol Ther 1978; 25: 316–23Google Scholar
  173. 173.
    Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients on carbamazepine or phenytoin. Epilepsia 1996; 37: 253–7PubMedGoogle Scholar
  174. 174.
    Arana GW. Carbamazepine-induced reduction of plasma alprazolam concentrations: a clinical case report. J Clin Psychiatry 1988: 49: 448PubMedGoogle Scholar
  175. 175.
    Leinonen E, Lillsunde P, Laukkanen V, et al. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991; 11: 313–8PubMedGoogle Scholar
  176. 176.
    Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1–12PubMedGoogle Scholar
  177. 177.
    Perucca E, Manzo L, Crema A. Pharmacokinetic interactions between antiepileptic and psychotropic drugs. In: Trimble MR, editor. The psychopharmacology of epilepsy. Chichester: J Wiley and Sons Ltd, 1985: 95–105Google Scholar
  178. 178.
    Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479–97Google Scholar
  179. 179.
    Spina E, Avenoso A, Campo GM, et al. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology Berl 1995; 117: 413–6PubMedGoogle Scholar
  180. 180.
    Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993; 15: 258–60PubMedGoogle Scholar
  181. 181.
    Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106–9PubMedGoogle Scholar
  182. 182.
    Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 219–22PubMedGoogle Scholar
  183. 183.
    Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. Psychopharmacology (Berl) 1994; 116: 115–6Google Scholar
  184. 184.
    Linnoila, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980; 13: 819–21Google Scholar
  185. 185.
    Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring: relevance during the drug treatment of psychiatric disorders. CNS Drugs 1995; 4: 432–53Google Scholar
  186. 186.
    Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993; 150: 169PubMedGoogle Scholar
  187. 187.
    Jerling M, Lindstrom L, Bonesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74PubMedGoogle Scholar
  188. 188.
    Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29: 172–91PubMedGoogle Scholar
  189. 189.
    Rapport DJ, Calabrese JR. Interactions between carbamazepine and birth control pills. Psychosomatics 1989; 30: 462–4PubMedGoogle Scholar
  190. 190.
    Back DJ, Grimmer SFM, Orme MLE, et al. Evaluation of Committee on Safety of Medicine yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32PubMedGoogle Scholar
  191. 191.
    Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892–6PubMedGoogle Scholar
  192. 192.
    Jubiz W, Meikle AW. Alterations of glucocorticoid actions by other drugs and disease states. Clin Pharmacokinet 1979; 18: 113–21Google Scholar
  193. 193.
    Bartoszek M, Brenner M, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987; 42: 424–32PubMedGoogle Scholar
  194. 194.
    Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy and in women using low-dose oral contraceptives. Biomed Pharmacother 1986: 40: 301–10PubMedGoogle Scholar
  195. 195.
    Privitera MR. Interference by carbamazepine with dexamethasone suppression test. Biol Psychiatry 1982; 17: 611PubMedGoogle Scholar
  196. 196.
    Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. BMJ 1980; 2: 1415–6Google Scholar
  197. 197.
    Kendall AG, Boivin M. Warfarin-carbamazepine interaction. Ann Intern Med 1981; 94: 280PubMedGoogle Scholar
  198. 198.
    Massey EW. Effect of carbamazepine on coumadin metabolism. Ann Neurol 1983; 13: 691–2PubMedGoogle Scholar
  199. 199.
    Hansen JM, Siersbaeck-Nielsen K, Kristensen M, et al. Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta Med Scand 1971; 189: 15–9PubMedGoogle Scholar
  200. 200.
    Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990; 83: 981PubMedGoogle Scholar
  201. 201.
    Lele P, Peterson P, Yang S, et al. Cyclosporin and tegretol: another drug interaction. Kidney Int 1985; 27: 344Google Scholar
  202. 202.
    Hillebrand G, Castro LA, van Scheidt, et al. Valproate for epilepsy in renal transplant recipients. Transplantation 1987; 43: 915–6PubMedGoogle Scholar
  203. 203.
    Alvarez JS, Del Castillo JAS, Ortiz MJA. Effect of carbamazepine on cyclosporin blood level. Nephron 1991; 58: 235–6Google Scholar
  204. 204.
    Szenohradszky J, Caldwell JE, Sharma ML, et al. Interaction of rocuronium (ORG9426) and phenytoin in a patient undergoing cadaver renal transplantation: a possible pharmacokinetic interaction? Anesthesiology 1994; 80: 1167–70PubMedGoogle Scholar
  205. 205.
    Alloul K, Varin F. Carbamazepine-induced changes in vecuronium pharmacokinetics in anaesthesized patients [abstract]. Clin Pharmacol Ther 1994; 55: 143Google Scholar
  206. 206.
    Melton AT, Antognini JF, Gronert CA. Prolonged duration of succinylcholine in patients receiving anticonvulsants: evidence for mild up-regulation of acetylcholine receptors? Can J Anaesth 1993; 40: 939–42PubMedGoogle Scholar
  207. 207.
    Hassan M, Oberg G, Bjorkholm M, et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181–6PubMedGoogle Scholar
  208. 208.
    Yue QT, Tomson T, Sawe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics 1994; 4: 193–8PubMedGoogle Scholar
  209. 209.
    Rodman JH, Murry DJ, Madded T, et al. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994; 12: 2390–7PubMedGoogle Scholar
  210. 210.
    Templehoff R, Modica PA, Spitznagel EL. Anticonvulsant therapy increases fentanyl requirements during anesthesia for craniotomy. Can J Anaesth 1990; 37: 327–32Google Scholar
  211. 211.
    Bonay M, Jonville-Bera AP, Diot P, et al. Possible interaction between phenobarbital, carbamazepine, and itraconazole. Drug Saf 1993; 9: 309–11PubMedGoogle Scholar
  212. 212.
    Michelucci R, Cipolla G, Gatti G, et al. Reduction of nisoldipine bioavailability by induction of first-pass metabolism in epileptic patients. Epilepsia. In pressGoogle Scholar
  213. 213.
    Bittencourt PRM, Gracia CM, Martins R, et al. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology 1992; 42: 492–6PubMedGoogle Scholar
  214. 214.
    Fleishacker JC, Hulst LK, Peters GR. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 1994; 56: 389–97Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Edoardo Spina
    • 1
  • Franco Pisani
    • 2
  • Emilio Perucca
    • 3
  1. 1.Institute of PharmacologyUniversity of MessinaMessinaItaly
  2. 2.Institute of Neurological and Neurosurgical SciencesUniversity of MessinaMessinaItaly
  3. 3.Clinical Pharmacology Unit, Department of Internal Medicine and TherapeuticsUniversity of PaviaPaviaItaly

Personalised recommendations